CLINICAL_TRIALS ClinicalTrials.gov record update

Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04664244
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:53.183454+00:00
Published At: 2020-12-22T00:00:00+00:00
Record Updated At: 2020-12-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Cervical Carcinoma", "Radiotherapy", "Epidermal Growth Factor Receptor", "Nimotuzumab", "Objective Response Rate", "Progression-free Survival", "Overall Survival"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-12-22"
protocolSection.identificationModule.nctId: "NCT04664244"
protocolSection.identificationModule.officialTitle: "Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.